Apricoxib

In today's world, Apricoxib has become a topic of great relevance and debate. Its impact covers various areas of society, from politics to popular culture. As time progresses, Apricoxib continues to be a topic of interest and analysis for experts and the general public. In this article, we will explore different aspects related to Apricoxib, from its origins to its influence on everyday life. In addition, we will examine the different perspectives and opinions around Apricoxib, with the aim of offering a comprehensive and complete view on this topic of global importance.

Apricoxib
Legal status
Legal status
  • Investigational
Identifiers
  • 4-benzenesulfonamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H20N2O3S
Molar mass356.44 g·mol−1
3D model (JSmol)
  • CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
  • InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)
  • Key:JTMITOKKUMVWRT-UHFFFAOYSA-N

Apricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID).[1] It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly-defined models of pancreatic cancer.[2] It was also studied in clinical trials for non-small-cell lung cancer.[3] Development was abandoned in 2015 due to poor clinical trial results.[4]

See also

References

  1. ^ "Apricoxib (Code C74021)". NCI Thesaurus. National Cancer Institute.
  2. ^ Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012). "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer". Clinical Cancer Research. 18 (18): 5031–42. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.
  3. ^ Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, et al. (January 2015). "Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer". Journal of Clinical Oncology. 33 (2): 189–94. doi:10.1200/JCO.2014.55.5789. PMC 4890680. PMID 25452446.
  4. ^ "Apricoxib". Adis Insight. Springer Nature Switzerland AG.
Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.